C. Caputo

A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants

S. Klein, J. Mankowski, C. Brayton, 2022, Journal of extracellular vesicles.

A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants

S. Klein, J. Mankowski, C. Brayton, 2021, bioRxiv.

Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children

A. Casadevall, S. Yoon, S. Klein, 2021, JCI insight.

Association of frailty, age, and biological sex with SARS-CoV-2 mRNA vaccine-induced immunity in older adults

S. Cramer, S. Klein, M. Betenbaugh, 2022, medRxiv.

Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine–Induced Immunity in Older Adults

S. Cramer, S. Klein, M. Betenbaugh, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection

A. Casadevall, S. Cramer, O. Laeyendecker, 2022, JCI insight.

Transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection: a double-blinded, phase 2 randomized, controlled trial

David M. Shade, A. Casadevall, B. Lau, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antibody Correlates of Protection for COVID-19 Convalescent Plasma Associated with Reduced Outpatient Hospitalizations

A. Casadevall, B. Lau, L. Appel, 2023, medRxiv.

Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection

A. Casadevall, B. Lau, L. Appel, 2021, medRxiv.